School of Continuing Education, Heilongjiang University of Traditional Chinese Medicine, Heping Road No. 24, Xiangfang District, Harbin City, Heilongjiang Province, China.
Drug Safety Evaluation Center of Heilongjiang University of Traditional Chinese Medicine, Heping Road No. 24, Xiangfang District, Harbin City, Heilongjiang Province, China.
J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Oct 1;1208:123400. doi: 10.1016/j.jchromb.2022.123400. Epub 2022 Jul 28.
Metabolomics can discover the biomarkers and metabolic pathways, provides the possibility for insights into the pharmacological action and mechanism of natural products. The therapeutic effect and mechanism of danshensu (DSS) on total metabolic pathways has not been well investigated. The aim of this study was to explore the disturbed endogenous biomarkers and metabolic pathways reflecting the pharmacological activity of DSS, and mechanism of action of DSS using comprehensive metabolome analysis based on high-throughput metabolomics technology combined with ultra-high performance liquid chromatography (UPLC) coupled with quadrupole tandem time-of-flight mass spectrometry (Q-TOF-MS) and pattern recognition method. Through the changes of the overall metabolic profile and the related biomarkers, the intervention effect of natural product danshensu (DSS) treatment on CHD model rats was revealed. The results showed that after the model replication was established, the metabolic profile was clearly separated, and a total of 26 potential biomarkers were screened out, and involving 8 metabolic pathways. After different doses of DSS solution were given, a total of 20 biomarkers could be significantly regulated, mainly involving primary bile acid biosynthesis, glycerophospholipid metabolism, and lipid metabolism. It showed UPLC-MS-based metabolomics can be used for discovering potential biomarkers and metabolic pathways of CHD, and to further understand and dissecting pharmacological effects and mechanisms of natural products via metabolomics techniques.
代谢组学可以发现生物标志物和代谢途径，为深入了解天然产物的药理作用和机制提供了可能性。丹酚酸（DSS）对总代谢途径的治疗效果和作用机制尚未得到很好的研究。本研究旨在通过基于高通量代谢组学技术的综合代谢组分析，结合超高效液相色谱（UPLC）与四极杆串联飞行时间质谱（Q-TOF-MS）和模式识别方法，探讨反映 DSS 药理活性和作用机制的内源性生物标志物和代谢途径的失调。通过整体代谢谱和相关生物标志物的变化，揭示天然产物丹酚酸（DSS）对 CHD 模型大鼠的干预作用。结果表明，在建立模型复制后，代谢谱明显分离，共筛选出 26 个潜在生物标志物，涉及 8 条代谢途径。给予不同剂量 DSS 溶液后，可显著调节 20 个生物标志物，主要涉及初级胆汁酸生物合成、甘油磷脂代谢和脂质代谢。结果表明，基于 UPLC-MS 的代谢组学可用于发现 CHD 的潜在生物标志物和代谢途径，并通过代谢组学技术进一步了解和剖析天然产物的药理作用和机制。
